Yeah agree - we shouldn't lost sight of revenue focus. Although it does seem like a lot is happening at once, as a long term investor I like the aggressive, broad net that CPH are casting.
Either they focus on the limited revenue streams (noting that many countries are yet to legalise cannabis and psychedelics) and increase profitability in the short term, or do they focus on expanding into as many industries as possible, in order to maximise potential revenue streams later on?
I think the answer to this question is really dependent on whether or not you're a short or long term holder.
That aside, you'll find that this new supplementary hemp feed is part of CPHs anibidiol product range, which doesn't require anywhere near the same levels of approval that you would expect for products designed for human consumption. This new hemp feed will go out to market very quickly, with initial orders expected in the coming weeks, as per the announcement.
CPH Price at posting:
17.3¢ Sentiment: Buy Disclosure: Held
